In this Q&A, hematologist Dr. Kwiatkowski discusses the Food and Drug Administration approval of beti-cel (Zynteglo®), a gene therapy for beta thalassemia.
CHOP was a leading study site in the clinical trials that led to the FDAs approval of this therapy for patients who require regular blood transfusions.